tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

PHRRF Stock Latest News

PharmaTher Closes in on FDA Ketamine Approval Date
Company AnnouncementsPharmaTher Closes in on FDA Ketamine Approval Date
16d ago
PharmaTher receives GDUFA goal date of October 29 for ketamine NDA
PremiumThe Fly
PharmaTher receives GDUFA goal date of October 29 for ketamine NDA
16d ago
PharmaTher Announces Update on FDA New Drug Application for Ketamine
PremiumPress Releases
PharmaTher Announces Update on FDA New Drug Application for Ketamine
16d ago
PharmaTher’s Potential Breakthrough in Monkeypox Treatment
PremiumCompany Announcements
PharmaTher’s Potential Breakthrough in Monkeypox Treatment
1M ago
PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins
PremiumPress Releases
PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins
1M ago
PharmaTher’s Sairiyo Advances with Clinical Trial Approval
PremiumCompany AnnouncementsPharmaTher’s Sairiyo Advances with Clinical Trial Approval
1M ago
PharmaTher’s Sairiyo receives approval to initiate Phase 1 trial of PD-001
Premium
The Fly
PharmaTher’s Sairiyo receives approval to initiate Phase 1 trial of PD-001
1M ago
PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)
Premium
Press Releases
PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)
1M ago
PharmaTher Advances Clinical Trials for New Treatment
PremiumCompany Announcements
PharmaTher Advances Clinical Trials for New Treatment
4M ago
PharmaTher’s Sairiyo submits CTA for Phase 1 study of cepharanthine
PremiumThe Fly
PharmaTher’s Sairiyo submits CTA for Phase 1 study of cepharanthine
4M ago
PharmaTher Nears FDA Decision on Ketamine Application
PremiumCompany Announcements
PharmaTher Nears FDA Decision on Ketamine Application
4M ago
PharmaTher announces assigned GDUFA goal data for Ketamine ANDA
PremiumThe Fly
PharmaTher announces assigned GDUFA goal data for Ketamine ANDA
4M ago
PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine
PremiumPress ReleasesPharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine
4M ago
PharmaTher Advances Cepharanthine Phase 1 Trials
Premium
Company Announcements
PharmaTher Advances Cepharanthine Phase 1 Trials
5M ago
PharmaTher’s Sairiyo completes package for Phase 1 study of cepharanthine
Premium
The Fly
PharmaTher’s Sairiyo completes package for Phase 1 study of cepharanthine
5M ago
PharmaTher Optimistic on Resolving Ketamine Shortage
PremiumCompany Announcements
PharmaTher Optimistic on Resolving Ketamine Shortage
5M ago
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
PremiumPress Releases
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
5M ago
PharmaTher Closer to Resolving US Ketamine Shortage
PremiumCompany Announcements
PharmaTher Closer to Resolving US Ketamine Shortage
5M ago
PharmaTher provides update on priority original ANDA for ketamine
PremiumThe Fly
PharmaTher provides update on priority original ANDA for ketamine
5M ago
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
PremiumPress ReleasesPharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
5M ago
Revive provides update on psilocybin study for methamphetamine use disorder
Premium
The Fly
Revive provides update on psilocybin study for methamphetamine use disorder
6M ago
PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia
Premium
Press Releases
PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia
7M ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >